MGNX (Macrogenics) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 28, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Macrogenics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Macrogenics's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Macrogenics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Macrogenics's Margin of Safety % (DCF Earnings Based) falls into.

Save Embed

;

Save Embed

;

Macrogenics Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Macrogenics's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

M55:Germany

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Executives

Jeffrey Stuart Peters	officer: Acting General Counsel	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
James Karrels	officer: SVP, CFO and Secretary	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Thomas Spitznagel	officer: Sr VP, BPD & Manufacturing	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Eric Blasius Risser	officer: Sr VP & Chief Business Officer	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Ezio Bonvini	officer: Sr VP, Research & CSO	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz	director
Margaret Liu	director	C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kenneth Galbraith	director	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck	officer: Chief Medical Officer	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949